Ultimovacs: Slight delay for INITIUM readout - Redeye

Redeye judges that Ultimovacs announcing a slight delay for its phase II INITIUM readout from H1 2023e to H2 2023e does not constitute a major change in the company’s equity story. We will adjust our estimates in our Q1 2023 report comment and do not expect to change our valuation significantly.

Länk till analysen i sin helhet: https://www.redeye.se/research/896889/ultimovacs-slight-delay-for-initium-readout?utm_source=finwire&utm_medium=RSS